June 10, 2024 (View All Issues)
Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC
Osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non–small-cell lung cancer (NSCLC) following definitive chemoradiotherapy. These findings of the phase III LAURA trial suggest that osimertinib may become a new...
Optimizing the Management of DCIS
“Ductal carcinoma in situ (DCIS), once a rare entity, now comprises 20% to 30% of newly diagnosed breast cancers detected on mammography and is appreciated to be a widely heterogeneous disease,” said E. Shelley Hwang, MD, MPH, the Mary and Deryl Hart Distinguished Professor at Duke University, who ...
Cardiotoxicity: How Far Have We Come?
A little more than 12 months ago, the first major cardio-oncology guidelines were published by the European Society of Cardiology (ESC).1 The extensive document embodied the immense progress of this subspecialty over its short existence.
In reaching this milestone, it is worth considering what...
Introducing ASPIRE and STORIES: A New International Initiative for Faculty Collaboration and Patient Advocacy in Immune-Related Adverse Events
The Immune-Related Adverse Events (irAE) Consortium has launched ASPIRE and STORIES with the aim of uniting clinicians, researchers, and patients to advance clinical care and advocacy. As the indications for immune checkpoint inhibitors in oncology have rapidly expanded over the past decade, the...
HPV Vaccine Shows Prevention Efficacy for Several Types of HPV-Related Cancers in Both Males and Females
According to the Centers for Disease Control and Prevention, since the human papillomavirus (HPV) vaccine was introduced in the United States in 2006, HPV infections that cause most HPV-related cancers and genital warts have decreased by 88% among teenage girls and 81% among young adult women. Now, ...
FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma
On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic...
AUA, ASCO, and SUO Publish 2024 Amendment to Nonmetastatic Muscle-Invasive Bladder Cancer Guidelines
The American Urological Association (AUA), in partnership with ASCO and the Society of Urologic Oncology (SUO), has issued a 2024 clinical practice guideline amendment for the diagnosis and treatment of nonmetastatic muscle-invasive bladder cancer. The updated guidelines were published by...
Pancreatic Surgeon Named New Director of Moores Cancer Center at UC San Diego Health
Following an extensive national search, Diane M. Simeone, MD, has been appointed Director of Moores Cancer Center at the University of California (UC) San Diego Health. Dr. Simeone brings institutional, national, and international leadership experience both to oncologic patient care and scientific...
NADINA Trial Shows Robust Benefit for Neoadjuvant Nivolumab Plus Ipilimumab in Stage III Melanoma
Results of the phase III NADINA trial support a new standard of care for the treatment of resectable macroscopic stage III melanoma. Treatment with preoperative ipilimumab plus nivolumab followed by total lymph node dissection, with adjuvant therapy guided by depth of response, led to a highly...
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
On May 30, the U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a...
Tepotinib for Metastatic NSCLC With MET Exon 14–Skipping Alterations
On February 15, 2024, tepotinib (Tepmetko)-—a kinase inhibitor directed against MET, including variants with exon 14 skipping—was granted regular approval for patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations.1
...
LEAP-001: Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets
The highly anticipated ENGOT-en9/LEAP-001 trial in endometrial cancer has missed both its primary endpoints. At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, the study investigators reported no significant benefit in progression-free survival or overall survival...
Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
On April 22, 2024, the interleukin-15 receptor agonist nogapendekin alfa inbakicept-pmln was approved for use with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.1
Supporting Efficacy Data
...
How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life
Several years ago, a visit to the National Air and Space Museum in Washington, DC, so fascinated and inspired Mace L. Rothenberg, MD, FASCO, about the history of flight, he wondered why there was not a similar museum showcasing the past and present achievements in science and medicine. The result...
Multiple Myeloma Survivor and Advocate Shares 12-Step Program: How Not to Die of Cancer
Facing mortality can be a paralyzing experience for some people, but for others, it may ignite a passion to accelerate life. One such person is Kathy Giusti, cofounder of the Multiple Myeloma Research Foundation (MMRF), where she served as Chief Executive Officer and President for nearly 20 years....
In Celebration of a Remarkable Life and Career in Oncology
When Jamie H. Von Roenn, MD, FASCO, graduated from high school in 1970 and enrolled at the University of Illinois in Champaign, she was determined to seek a career in special education, because she wanted to “help people through difficult situations.” Although Dr. Von Roenn ultimately decided to...
I Am Living With Recurring Stage IV Colorectal Cancer
Despite urgings from my primary care physician to get a colonoscopy screening after I turned 50, I resisted. As a health-care provider, and someone who is tuned into changes in my body, I thought I would instinctively know if I had a serious illness. I was wrong. Even after finally relenting to at...
FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team,...
Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma
An ASCO guideline update offers new recommendations on systemic treatment for advanced hepatocellular carcinoma (HCC), based on promising findings from several recent randomized controlled trials as well as the approval of new first- and second-line immunotherapy combinations.1
“This guideline...
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease.
The staging system, developed by surgical oncologist...
